Drugs & Therapy Perspectives

, Volume 16, Issue 11, pp 12–16 | Cite as

Important to consider HR-QOL when treating patients with RA

Drug economics and quality of life


Rheumatoid Arthritis Methotrexate Actinic Keratosis Health Assessment Questionnaire Toxicity Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nichol MB, Harada ASM. Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis: a review. Pharmacoeconomics 1999 Nov; 16 (5 Pt 1): 433–48PubMedCrossRefGoogle Scholar
  2. 2.
    Scaling methods. Available from: [Accessed 2000 Oct 10]
  3. 3.
    Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36 (5): 551–9PubMedCrossRefGoogle Scholar
  4. 4.
    Liang MH, Larson MG, Cullen KE, et al. Comparative measurement efficacy and sensitivity of 5 health status instruments for arthritis research. Arthritis Rheum 1985; 28: 542–7PubMedCrossRefGoogle Scholar
  5. 5.
    Fries JF. Quality-of-life considerations with respect to arthritis and nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (3A): 14S–2205PubMedCrossRefGoogle Scholar
  6. 6.
    Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheumatism 1998; 41 (5): 778–99PubMedCrossRefGoogle Scholar
  7. 7.
    Bendtsen P, Åkerlind I, Hörnquist J. Pharmacological intervention in older patients with rheumatoid arthritis: quality of life aspects. Drugs Aging 1995; 7 (5): 338–46PubMedCrossRefGoogle Scholar
  8. 8.
    Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. Pharmacoeconomics 1994; 6 (6): 513–22PubMedCrossRefGoogle Scholar
  9. 9.
    Bendtsen P, Åkerlind I, Hörnquist JO. Assessment of quality of life in rheumatoid arthritis: methods and implications. Pharmacoeconomics 1994; 5 (4): 286–98PubMedCrossRefGoogle Scholar
  10. 10.
    Alarcon GS. Epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 1995; 21 (2): 589–604PubMedGoogle Scholar
  11. 11.
    Ganz PA. Methods of assessing the effect of drug therapy on quality of life. Drug Saf 1990; 5 (4): 233–42PubMedCrossRefGoogle Scholar
  12. 12.
    Fries JF. The hierarchy of quality-of-life assessment, the Health Assessment Questionnaire (HAQ), and issues mandating development of a toxicity index. Control Clin Trials 1991; 12 (4 Suppl.): 106S–17SPubMedCrossRefGoogle Scholar
  13. 13.
    Scott DL, Shipley M, Dawson A, et al. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. Br J Rheumatol 1998; 37: 546–54PubMedCrossRefGoogle Scholar
  14. 14.
    Group for the Respect of Ethics and Excellence in Science (GREES): Rheumatoid Arthritis Section. Recommendation for the registration of drugs used in the treatment of rheumatoid arthritis. Br J Rheumatol 1998; 37: 211–5CrossRefGoogle Scholar
  15. 15.
    Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. Arthritis Rheum 1992; 35: 1117–25PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Personalised recommendations